KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Long-Term Deferred Tax: 2016-2019

Historic Long-Term Deferred Tax for Supernus Pharmaceuticals (SUPN) over the last 4 years, with Dec 2019 value amounting to $32.1 million.

  • Supernus Pharmaceuticals' Long-Term Deferred Tax was N/A to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.8 million, marking a year-over-year change of. This contributed to the annual value of $32.1 million for FY2019, which is 8.02% up from last year.
  • As of FY2019, Supernus Pharmaceuticals' Long-Term Deferred Tax stood at $32.1 million, which was up 8.02% from $29.7 million recorded in FY2018.
  • In the past 5 years, Supernus Pharmaceuticals' Long-Term Deferred Tax ranged from a high of $41.7 million in FY2016 and a low of $20.8 million during FY2017.
  • In the last 3 years, Supernus Pharmaceuticals' Long-Term Deferred Tax had a median value of $29.7 million in 2018 and averaged $27.5 million.
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first tumbled by 50.05% in 2017, then surged by 42.41% in 2018.
  • Yearly analysis of 4 years shows Supernus Pharmaceuticals' Long-Term Deferred Tax stood at $41.7 million in 2016, then plummeted by 50.05% to $20.8 million in 2017, then surged by 42.41% to $29.7 million in 2018, then climbed by 8.02% to $32.1 million in 2019.